Table 2. Association analysis between genetic polymorphisms and AD.
| SNP | (Nearby) gene, full name | Minor allele | MAF | Genetic model | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Additive | Dominant | Recessive | |||||||||||
| AD cases (n=425) | Controls (n=460) | OR (95% CI) | P | Pcor. | OR (95% CI) | P | Pcor. | OR (95% CI) | P | Pcor. | |||
| rs6682925 | IL23R, Interleukin 23 receptor | C | 0.424 | 0.403 | 1.15 (0.89–1.48) | 0.29 | - | 0.96 (0.66–1.41) | 0.84 | - | 1.69 (1.06–2.70) | 0.03 | NS |
| rs7622183 | IL5RA, Interleukin 5 receptor subunit alpha | T | 0.464 | 0.517 | 0.74 (0.57–0.96) | 0.02 | NS | 0.66 (0.44–0.99) | 0.05 | - | 0.69 (0.45–1.06) | 0.09 | - |
| rs17454584 | (IL2, Interleukin 2) | G | 0.127 | 0.101 | 1.69 (1.14–2.50) | 0.009 | NS | 1.78 (1.16–2.72) | 0.008 | NS | 1.76 (0.34–9.06) | 0.50 | - |
| rs17389644 | (IL21, Interleukin 21) | A | 0.127 | 0.103 | 1.75 (1.17–2.61) | 0.006 | NS | 1.86 (1.20–2.87) | 0.005 | NS | 1.79 (0.34–9.35) | 0.49 | - |
| rs10214237 | (IL7R, Interleukin 7 receptor) | C | 0.173 | 0.179 | 1.00 (0.71–1.41) | 0.99 | - | 1.00 (0.76–1.31) | 0.99 | - | 1.00 (1.00–1.01) | 0.97 | - |
| rs13361382 | TMEM232, Transmembrane protein 232 | A | 0.125 | 0.106 | 1.02 (0.67–1.55) | 0.92 | - | 1.05 (0.67–1.64) | 0.85 | - | 0.59 (0.11–3.21) | 0.54 | - |
| rs6871536 | RAD50, RAD50 double strand break repair protein/TH2LCRR, T helper type 2 locus control region associated RNA | C | 0.211 | 0.185 | 1.23 (0.89–1.71) | 0.21 | - | 1.35 (0.92–1.98) | 0.12 | - | 0.91 (0.34–2.40) | 0.84 | - |
| rs2569190 | CD14, CD14 molecule/TMCO6, Transmembrane and coiled-coil domains 6 | G | 0.364 | 0.384 | 0.90 (0.68–1.18) | 0.45 | - | 0.83 (0.57–1.19) | 0.31 | - | 1.00 (0.57–1.74) | 0.99 | - |
| rs11741861 | IRGM, Immunity related GTPase M/ZNF300, Zinc finger protein 300 | G | 0.376 | 0.365 | 1.26 (0.96–1.64) | 0.09 | - | 1.19 (0.82–1.72) | 0.36 | - | 1.72 (1.02–2.90) | 0.04 | NS |
| rs4713555 | (HLA-DRB1, Major histocompatibility complex class II DR beta 1/HLA-DQA1, Major histocompatibility complex class II DQ alpha 1) | T | 0.326 | 0.281 | 1.32 (1.00–1.76) | 0.05 | - | 1.34 (0.93–1.92) | 0.12 | - | 1.73 (0.91–3.28) | 0.09 | - |
| rs2275913 | IL17A, Interleukin 17A | A | 0.443 | 0.431 | 0.97 (0.75–1.27) | 0.83 | - | 0.84 (0.57–1.25) | 0.39 | - | 1.17 (0.73–1.87) | 0.51 | - |
| rs9357733 | EFHC1, EF-hand domain containing 1 | G | 0.309 | 0.338 | 0.95 (0.73–1.25) | 0.72 | - | 0.91 (0.63–1.32) | 0.62 | - | 1.00 (0.57–1.75) | 0.99 | - |
| rs4271002 | NAT2, N-acethyltransferase 2 | C | 0.221 | 0.223 | 0.98 (0.72–1.34) | 0.91 | - | 1.03 (0.71–1.48) | 0.89 | - | 0.75 (0.31–1.82) | 0.53 | - |
| rs6473227 | (ZBTB10, Zinc finger and BTB domain containing 10) | A | 0.358 | 0.427 | 0.72 (0.56–0.93) | 0.01 | NS | 0.74 (0.51–1.07) | 0.10 | - | 0.50 (0.30–0.83) | 0.008 | |
| rs4246905 | TNFSF15, TNF superfamily member 15 | T | 0.329 | 0.330 | 0.94 (0.72–1.23) | 0.66 | - | 0.96 (0.67–1.38) | 0.82 | - | 0.84 (0.47–1.50) | 0.56 | - |
| rs2212434 | (EMSY, EMSY BRCA2 interacting transcriptional repressor) | C | 0.474 | 0.516 | 0.79 (0.61–1.01) | 0.06 | - | 0.81 (0.53–1.22) | 0.32 | - | 0.64 (0.42–0.98) | 0.04 | NS |
| rs2143950 | (PPP2R3C, Protein phosphatase 2 regulatory | T | 0.403 | 0.353 | 1.30 (1.00–1.71) | 0.05 | - | 1.51 (1.04–2.19) | 0.03 | NS | 1.21 (0.71–2.06) | 0.49 | - |
P value of logistic regression analysis by adjusting age and sex as covariates. Bold values indicate the statistical significance of P<0.05. Pcor. value corrected for multiple testing (effective number of correction=15.98) using the SNPSpD program.
AD, atopic dermatitis; SNP, single nucleotide polymorphism; MAF, minor allele frequency; OR, odds ratio; CI, confidence interval; NS, not significant.